Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1/2 1Phase 1 1

Status

Recruiting 3Terminated 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Endocrine 5NET 4Gastrointestinal 3CNS 1

Conditions

Neuroendocrine Tumors 3Gastro-enteropancreatic neuroendocrine tumor 2Carcinoid Tumor 1Adenoma, Islet Cell 1Acromegaly 1

Interventions

lutetium Lu 177 dotatate 29Magnetic Resonance Spectroscopy 15Everolimus 10pembrolizumab 9Specimen Handling 9cabozantinib 7Nivolumab 7Lutetium-177 6surufatinib 5lenvatinib 5Octreotide 5Capecitabine 5177Lu-octreotide, DOTA(0)-Tyr(3)- 5olaparib 4lanreotide 4gallium Ga 68 dotatate 4amino-acid, glucose, and electrolyte solution 4X-Rays 4Lutetium 4Ipilimumab 4Injections 4Fluorodeoxyglucose F18 4copper dotatate CU-64 3atezolizumab 3Temozolomide 3Ga(III)-DOTATOC 3Cyclophosphamide 3Carboplatin 3pasireotide 2fludarabine phosphate 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
lanreotide × NET × 1 year × Clear all
NCT05048901 2026-04-09

Cabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine Tumors

National Health Research Institutes, Taiwan

Phase 1/2 Recruiting
49 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT05477576 2026-03-30

ACTION-1

RayzeBio, Inc.

Phase 3 Recruiting
338 enrolled
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Carcinoid Tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

NCT05364944 2025-11-17

OXTEND-01

Debiopharm International SA

Phase 1 Terminated
19 enrolled
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Acromegaly

NCT06878664 2025-09-02

RIALTO

Grupo Espanol de Tumores Neuroendocrinos

Phase 3 Recruiting
166 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡